-
3 weeks ago | 
dermatologytimes.com | Jonathan I. Silverberg |Kaitlyn Bader
"RAD was created to address this amazing increase in knowledge and treatment options that we have now for atopic dermatitis. It's hard for the clinician who's busy in the trenches to keep up with all the data and to really gain insights into all these new therapies that kind of hit us at once, and are still coming really fast and furious," said Jonathan Silverberg, MD, PhD, MPH, in an interview with Dermatology Times.
-
Oct 7, 2024 | 
hcplive.com | Christopher G. Bunick |Lindsay S. Ackerman |Jonathan I. Silverberg
OpinionVideoOctober 7, 2024Author(s): Emerging therapies, including biologics and small molecules, are promising for moderate to severe atopic dermatitis management. Clinicians should adopt a personalized approach, considering patient-specific factors and maintaining open communication. Integrating new therapies with existing regimens can enhance treatment outcomes for atopic dermatitis patients.
-
Oct 7, 2024 | 
consultantlive.com | Christopher G. Bunick |Lindsay S. Ackerman |Jonathan I. Silverberg
Treatment Advances and Evolving Standard of Care in Atopic Dermatitis - Episode 17Published on: , , Looking to the future of atopic dermatitis treatment, the panel discusses ongoing research and promising emerging therapies. Video content above is prompted by the following:Are there any ongoing atopic dermatitis studies or emerging therapies that you are excited about? What advice would you like to share with clinicians taking care of patients with moderate/severe atopic dermatitis?
-
Sep 23, 2024 | 
hcplive.com | Christopher G. Bunick |Lindsay S. Ackerman |Jonathan I. Silverberg
September 23, 2024By Atopic dermatitis, AD, JAK inhibitors, AD treatment, atopic dermatitis treatment, long-term safety, safety, herpes zosterVideo content above is prompted by the following:Are there any learnings from long-term upadacitinib data that were not seen in short-term data? What about short vs long-term data with other JAKi? How do they impact your use of JAKi for atopic dermatitis? Related Content Related Content
-
Sep 23, 2024 | 
hcplive.com | Christopher G. Bunick |Lindsay S. Ackerman |Jonathan I. Silverberg
September 23, 2024By Jonathan Silverberg, MD, PhD, MPH, reviews findings from the LEVEL UP study investigating upadacitinib in patients with moderate-to-severe atopic dermatitis. Video content above is prompted by the following:Please discuss Level Up data with upadacitinib that were recently presented at RAD 2024. What are clinical implications of these data for everyday practice? Related Content Related Content
-
Sep 16, 2024 | 
hcplive.com | Christopher G. Bunick |Lindsay S. Ackerman |Jonathan I. Silverberg
September 16, 2024By Experts on atopic dermatitis compare the safety profile of JAK inhibitors with traditional and more advanced treatments currently available for patients. Video content above is prompted by the following:Discuss safety of JAKi compared to traditional and more advanced treatments for atopic dermatitis. Boxed warning for JAKiWhat are primary concerns for physicians and patients? Related Content Related Content
-
Sep 16, 2024 | 
hcplive.com | Christopher G. Bunick |Lindsay S. Ackerman |Jonathan I. Silverberg
September 16, 2024By Lindsay S. Ackerman, MD, FAAD, and Jonathan Silverberg, MD, PhD, MPH, provide clinical insights on best practices for monitoring patients with atopic dermatitis who are receiving JAK inhibitors. Video content above is prompted by the following:What is the recommended monitoring schedule for JAKi? Do you communicate it with patients when selecting treatment? Related Content Related Content
-
Sep 9, 2024 | 
hcplive.com | Christopher G. Bunick |Lindsay S. Ackerman |Jonathan I. Silverberg
September 9, 2024By A panel of dermatologists discuss the evolution of JAK inhibitors for atopic dermatitis and how they fit into current treatment paradigms. Video content above is prompted by the following:A number of JAK inhibitors, both oral (abrocitinib, upadacitnib) and topical (ruxolitinib cream), are FDA approved for atopic dermatitis. How have JAK inhibitors evolved over the years? How have differences between JAK inhibitors led to differences in their safety and efficacy profiles?
-
Sep 9, 2024 | 
hcplive.com | Christopher G. Bunick |Lindsay S. Ackerman |Jonathan I. Silverberg
September 9, 2024By Focusing on the complex pathophysiology of atopic dermatitis, Lindsay S. Ackerman, MD, FAAD, discusses the importance of looking beyond type 2 inflammation while treating patients. Video content above is prompted by the following:With better understanding of the pathophysiology of atopic dermatitis, how important is to look beyond type 2 inflammation? Related Content Related Content
-
Sep 2, 2024 | 
hcplive.com | Christopher G. Bunick |Jonathan I. Silverberg |Lindsay S. Ackerman
Unmet Needs and Gaps in ADDermatologists outline unmet needs in the treatment landscape for atopic dermatitis and discuss how to potentially improve the standard of care for patients with atopic dermatitis.
